Cellectis S.A, University of Texas MD Anderson Cancer Center deal

MD Anderson and Cellectis partnered to co-develop four allogeneic chimeric antigen receptor T cell

Read the full 149 word article

How to gain access

Continue reading with a
two-week free trial.